Chloramphenicol

Synonyms: 氯霉素
Chloramphenicol 是一种口服有效的广谱抗生素,具有抗菌活性,可抑制缺氧 A549 和 H1299 细胞中氧不稳定转录因子和缺氧诱导因子-1α (HIF-1α),并抑制血管内皮生长因子 (VEGF) 和葡萄糖转运蛋白 1 (glucose transporter 1) 的 mRNA 水平,最终降低 VEGF 的释放,可用于厌氧菌感染和肺癌研究。
产品编号: MS-E21076 纯度: 99.96% CAS No.: 56-75-7 分子式: C11H12Cl2N2O5 分子量: 323.13
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
询价
50g
询价
询价

产品描述

Chloramphenicol 是一种口服有效的广谱抗生素,具有抗菌活性,可抑制缺氧 A549 和 H1299 细胞中氧不稳定转录因子和缺氧诱导因子-1α (HIF-1α),并抑制血管内皮生长因子 (VEGF) 和葡萄糖转运蛋白 1 (glucose transporter 1) 的 mRNA 水平,最终降低 VEGF 的释放,可用于厌氧菌感染和肺癌研究。

生物实验数据

生物活性 Chloramphenicol is an orally effective broad-spectrum antibiotic with antibacterial activity that inhibits oxygen-labile transcription factors and hypoxia-inducible factor-1α (HIF-1α) in hypoxic A549 and H1299 cells, suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, ultimately reducing VEGF release, and can be used for research on anaerobic infections and lung cancer.
IC50 & Target protozoan motility:2.95 ± 0.25 mM
体外研究
(In Vitro)

Chloramphenicol (1-100 μg/mL, 18-24 h) inhibits the HIF-1α pathway in NSCLC cells in a concentration-dependent manner.
Chloramphenicol (100 μg/mL, 0-24 h) induces autophagy in NSCLC cells, substantially increases the levels of autophagic biomarkers (beclin-1, Atg12-Atg5 conjugates, and LC3-II).
Chloramphenicol induces abnormal differentiation and inhibits apoptosis in activated T cells.
Chloramphenicol can inhibit both bacterial and mitochondrial protein synthesis, causing mitochondrial stress and decreased ATP biosynthesis.
chloramphenicol (1-100 μg/mL) can induce matrix metalloproteinase (MMP)-13 expression and increase MMP-13 protein.
chloramphenicol (1-100 μg/mL) can activate c-Jun N-terminal kinases (JNK) and phosphatidylinositol 3-kinase (PI-3K)/Akt signaling, leading to c-Jun protein phosphorylation.
Chloramphenicol acts primarily on the 50S subunit of bacterial 70S rihosomes and inhibits peptide bond formation by suppressing peptidyl transferase activity.

Cell Viability Assay

Cell Line: A549 and H1299 cells
Concentration: 0, 1, 10, 100 μg/mL
Incubation Time: 3 h and 24 h
Result: In the 3-h-treated group, the viability of A549 and H1299 cells at 100 μg/mL concentration was 97.0 ± 3.9% and 98.1 ± 5.0%, respectively. The viability of A549 cells was 102.9 ± 1.3% and 99.2 ± 0.9%, whereas the viability of H1299 cells was 103.3 ± 1.9% and 93.8 ± 4.5%, under hypoxia and treatment with CoCl2, respectively.

Western Blot Analysis

Cell Line: A549 and H1299 cells
Concentration: 0, 1, 10, 50, 100 μg/mL
Incubation Time: 18-24 h
Result: Inhibited HIF-1α protein accumulation in NSCLC cells in a concentration-dependent manner, while the expression levels of ARNT remained unaltered. Had no effect on CoCl2 (250 μM, 3 h treatment)-mediated HIF-1α protein accumulation and SENP-1 protein reduction.

Western Blot Analysis

Cell Line: A549 and H1299 cells
Concentration: 100 μg/mL
Incubation Time: 0, 6, 12, 24 h
Result: Induced autophagy in NSCLC cells in a time-dependent manner. Upregulats the expression of beclin-1 and increased the levels of Atg12-Atg5 conjugates in both NSCLC cell lines, both in a time dependent and concentration-dependent manner. Augmented LC3-II and downregulated p62/STSQM1 in A549 cells. Induced an augmentation of p62/STSQM1, and a decrease in LC3-II levels in H1299 cells.
体内研究
(In Vivo)

Chloramphenicol (0-3500 mg/kg, Gavage, daily, for 5 days) decreases erythrocytes and erythrocyte precursors and reduces marrow erythroid cells were at day 1 post-dosing, and returns to normal by 14 days post-dosing.

Animal Model: Female B6C3F1 mice (12-14 weeks old)
Dosage: 0, 2500 and 3500 mg/kg
Administration: Gavage, daily, for 5 days
Result: Cessation of erythropoiesis was evident at day 1 post-dosing. A recovery was seen at day 7 post-dosing at the 2500 mg/kg dose level and at between 7 and 14 days at the 3500 mg/kg dose level. Myelotoxicity was most pronounced in the erythroid series at each dose level. Depressed femoral marrow BFU-E and CFU-E at day 1 post-dosing. All the blood and marrow parameters in the present study returned to normal by 14 days post-dosing.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT05028907Sohag University
Ophthalmopathy , Lacrimal System
2020-11-15PHASE4
性状 固体
颜色 White to off-white

化学信息

分子量 323.13
分子式 C11H12Cl2N2O5
CAS No. 56-75-7
别名 氯霉素

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.00 mg/mL (15.47 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years

*该产品在溶液状态不稳定,建议您现用现配,即刻使用。

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 150 mg/mL (464.21 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 100 mg/mL (309.47 mM; 超声助溶)

H2O 中的溶解度 : 3.06 mg/mL (9.47 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / Ethanol / DMSO1 mM3.0947 mL15.4736 mL30.9473 mL77.3682 mL
5 mM0.6189 mL3.0947 mL6.1895 mL15.4736 mL
Ethanol / DMSO10 mM0.3095 mL1.5474 mL3.0947 mL7.7368 mL
15 mM0.2063 mL1.0316 mL2.0632 mL5.1579 mL
20 mM0.1547 mL0.7737 mL1.5474 mL3.8684 mL
25 mM0.1238 mL0.6189 mL1.2379 mL3.0947 mL
30 mM0.1032 mL0.5158 mL1.0316 mL2.5789 mL
40 mM0.0774 mL0.3868 mL0.7737 mL1.9342 mL
50 mM0.0619 mL0.3095 mL0.6189 mL1.5474 mL
60 mM0.0516 mL0.2579 mL0.5158 mL1.2895 mL
80 mM0.0387 mL0.1934 mL0.3868 mL0.9671 mL
100 mM0.0309 mL0.1547 mL0.3095 mL0.7737 mL

* 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础